Limitations, agreements, and source contact

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer · Source last updated 2026-08-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

point Of Contact

email

heidi.roschitzki@etop.ibcsg.org

organization

ETOP IBCSG Partners Foundation

phone

+41 31 511 94 00

title

Dr. Heidi Roschitzki-Voser, Head Trial Activities/Deputy Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice